TY - JOUR T1 - Serial population-based sero-surveys for COVID-19 in low and high transmission neighborhoods of urban Pakistan JF - medRxiv DO - 10.1101/2020.07.28.20163451 SP - 2020.07.28.20163451 AU - Muhammad Imran Nisar AU - Nadia Ansari AU - Farah Khalid AU - Mashal Amin AU - Hamna Shahbaz AU - Aneeta Hotwani AU - Najeeb Rehman AU - Sierra Pugh AU - Arjumand Rizvi AU - Arslan Memon AU - Zahoor Ahmed AU - Ashfaque Ahmed AU - Junaid Iqbal AU - Ali Faisal Saleem AU - Uzma Bashir Aamir AU - Daniel B Larremore AU - Bailey Fosdick AU - Fyezah Jehan Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/12/28/2020.07.28.20163451.abstract N2 - Objective To determine population-based estimates of COVID-19 in a densely populated urban community of Karachi, Pakistan.Methods Three cross-sectional surveys were conducted in April, June and August in low- and high-transmission neighborhoods of Karachi. Participants were randomly selected to provide blood for Elecsys® immunoassay for detection of anti-SARS-CoV-2 antibodies. Bayesian regression model was used to estimate seroprevalence after adjusting for the demographic characteristics of each district. Conditional Risk of Infection (CRI) with 95% confidence interval was calculated using a non-parametric bootstrap of households. Infection fatality rates (IFR) were estimated.Results We enrolled 3005 participants from 623 households. In Phase 2, the adjusted seroprevalence was estimated as 8.7% (95% CI 5.1-13.1) and 15.1% (95% CI 9.4 -21.7) in low and high transmission areas respectively, compared to 0.2% (95% CI 0-0.7) and 0.4% (95% CI 0 - 1.3) in Phase 1. In Phase 3, it was 12.8% (95% CI 8.3 – 17.7) and 21.5% (95% CI 15.6-28) in low and high transmission areas, respectively. CRI was 0.31 (95% CI 0.16-0.47) and 0.41(95% CI 0.28-0.52) in low and high transmission neighborhoods respectively in Phase 2. Similar trends were observed in Phase 3. Only 5.4% of participants who tested positive for COVID-19 were symptomatic. IFR was 1.66% in phase 1, 0.37% in Phase 2 and 0.26% in Phase 3.Conclusion Initial rapid increase in seroprevalence was followed by a plateau in the later phase of the pandemic in Karachi. Continuing rounds of seroprevalence studies have the potential to fully characterize the pandemic in this geography.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was funded by Infectious Disease Research Lab at The Aga Khan UniversityAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethical approval was obtained from Aga Khan University's Ethical review committeeAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData will be made available on request ER -